tbuckley/cabot-search huggingface dataset:
Clinical Surgery for the Instruction of Practitioners and Students of Surgery.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Durable complete responses and near complete responses to sunitinib in metastatic renal cell carcinoma
Authors: D. Y. Heng, B. I. Rini, J. Garcia, L. Wood, R. M. Bukowski
Journal: Journal of Clinical Oncology (2007)

15514 Introduction: Sunitinib is a tyrosine kinase inhibitor with activity against VEGFR and PDGFR recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). There is no existing literature that details complete responses (CRs) in patients taking sunitinib for metastatic RCC. Methods: Seventy-four patients with metastatic RCC receiving sunitinib at the Cleveland Clinic Taussig Cancer Center on clinical trials were reviewed to determine the number of patients with RECIST-defined CRs. Additionally, patients who achieved near-CRs defined as a greater than 90% reduction in composite tumor volume or residual disease of less than or equal to 1 cm were reviewed. Results: Two patients (2.7%) achieved a RECIST-defined CR lasting &gt;15 months. The patients who obtained CRs had non-bulky pulmonary metastases, favorable or intermediate MSKCC risk profiles, were treated with sunitinib in the first-line setting and had a significant reduction in composite tumor measurements within the first two cycles. An additional 2 patients achieved near-CRs, including one patient that previously progressed on bevacizumab. These 2 near-CR patients remain progression-free for more than 19 months. Finally, 1 patient achieved sufficient downstaging and reduction of tumor volume such that the remaining lesion could be excised, resulting in a surgical CR. This patient is currently off sunitinib and remains progression-free 4 months after surgery. Conclusion: Sunitinib is capable of producing durable CRs in cytokine-naïve metastatic RCC patients with non-bulky pulmonary metastases. Additionally, near-CRs can be seen despite non-pulmonary metastatic sites and prior VEGF-targeted therapy. No significant financial relationships to disclose.
Massive early proteinuria following renal homotransplantation
Authors: G. M. Abouna
Journal: JAMA (1973)

Massive proteinuria (more than 40 gm/24 hr) occurred in a young man almost immediately after renal transplantation with an intrafamilial donor. The proteinuria, accompanied by severe hypoalbuminemia and extensive peripheral edema, persisted for several months and then subsided spontaneously. Histological and immunofluorescent examination of renal tissue showed no evidence of rejection or recurrent nephritis. We attribute the proteinuria to an increase in venous pressure within the kidney caused by ligation of one of two large renal veins draining the donor organ. The spontaneous remission is attributed to the development of adequate collateral venous channels, which acted to relieve the venous hypertension. When a renal homograft has two veins of similar size, both must be used for anastomosis.
AGC1 Deficiency Associated with Global Cerebral Hypomyelination
Journal: New England Journal of Medicine (2009)

notices can be as "life threatening" as diseases that have an inevitable fatal outcome.Chronic diseases challenge even the most skilled health care providers and strain a health care system that is poorly equipped to provide the necessary care.Coexisting conditions compound the management of chronic illness, and good options for treatment are frequently limited.Finally, the costs associated with chronic disease are truly alarming.For example, arthritis and related diseases -the most common causes of disability -currently affect 46 million people in the United States at an annual cost of $128 billion.These numbers are staggering, and they are projected to increase exponentially over the next two decades.This fact alone should add a sense of urgency to the quest to address the problem of chronic disease, which must be front and center if we ever hope to achieve effective and meaningful health care.This book captures the thoughts and emotions of coauthor Alida Brill -in whom an atypical form of Wegener's granulomatosis developed at a young age -along with the thoughts and experiences of coauthor Michael Lockshin, a rheumatologist who has cared for Brill throughout her illness.We learn very little about Brill's disease or how it is managed, but we learn everything about how profoundly it affects her.She goes through periods of denial, anger, fear, hope, and resignation, which give way to her acceptance of her illness as a "life sentence."Her relationship with Lockshin is built on trust, respect, and openness, and it becomes fundamental as they navigate her illness, even while they keep their distance and independence from one another.Their solution for effective health care is simple and straightforward -the focus must be on the patient.Together, Brill and Lockshin work to maintain Brill's "dignity, mobility, [and] independence," which would seem to be goals of every patient facing a serious chronic illness.Chapters alternate between Brill's writings and Lockshin's writings, and over the course of the book the two narrative threads seem to merge into one, with the recognition that the authors are very similar people -both are fiercely independent, caring, and working to protect people from the health care system.Their writings are poetic, revealing, insightful, and at times shocking in their honest and frank discussion of aspects of chronic disease that are rarely brought out into the open.
Otorhinolaryngology
Authors: B. R. Alford
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection
Authors: S Hellier
Journal: Hepatology (2003)

The effect of host genetic variation on the outcome of hepatitis C virus (HCV) infection and its treatment is poorly understood. The chemokine receptors CCR5, CCR2, and CCR3 and their ligands, RANTES, MCP-1, MCP-2, and MIP-1α, are involved in the immune responses and the selective recruitment of lymphocytes to the liver in HCV infection. We studied 20 polymorphisms within these genes and investigated their association with persistent carriage of HCV, severity of liver disease, hepatic inflammation, and response to treatment in a large European cohort. Significant associations were found between CCR5-Δ32 and reduced portal inflammation (P = .011, odds ratio [OR]: 2.3, 95% confidence interval [CI]: 1.09-4.84) and milder fibrosis (P = .015, OR: 1.97, 95% CI: 1.13-3.42). A promoter polymorphism at position −403 in the RANTES gene was associated with less severe portal inflammation (P = .004). An amino acid change in MCP2, Q46K, was associated with severity of fibrosis (P = .018, OR: 2.29, 95% CI: 1.14-4.58). In conclusion, our study suggests a possible role of the polymorphisms CCR5-Δ32, RANTES −403, and MCP-2 Q46K in the outcome of HCV infection. (Hepatology 2003;38:1468-1476.)
Jeremy Swan
Journal: BMJ (2005)

invented the Swan-Ganz cardiac catheter and was at the forefront of advances in cardiology for 40 years.A former president of the American College of Cardiology, Swan was an intellectual maverick who had vision, compassion, and wit.His cardiac catheter, made with a student of his called Willie Ganz, revolutionised heart surgery at its invention in 1968.It enabled bedside monitoring in critically ill patients by measuring heart output and capillary pressure in the lungs.This hugely improved the survival of patients with heart attacks, serious burns, acute respiratory failure, and many other conditions.Swan was born in Sligo Town, Ireland, the son of two general practitioners, and educated at Castle Knock School.From there he went to St Vincent's College, Dublin, but his studies were soon interrupted by meningitis and he lapsed into a coma.Penicillin was not yet available, but his mother gave him sulfa drugs, which saved his life.He recovered completely, both as a scholar and as a middle weight boxer.At St Thomas' Hospital Medical School his fellow students regarded him as a genius, and indeed, he was allowed to take his MRCP exams after six months instead of the usual two years.After six months as a casualty surgeon he did two years' war service with the Royal Air Force, mainly stationed at a military hospital in Iraq.Returning to St Thomas', he spent three years as physiology lecturer and was awarded a PhD for his early work on cardiac catheterisation and pharmacology, researching under Henry Barcroft, a historic figure in heart physiology.
Pertussis disease, vaccine, and controversy
Authors: V. A. Fulginiti
Journal: JAMA (1984)

Whooping cough affected as many as 265,000 persons and killed 9,000 to 12,000 at its peak in the United States in the 1930s.<sup>1</sup>Today, five to 20 persons die each year and the disease has been reduced to 1,000 to 2,000 cases per year. Pertussis vaccine was widely introduced in the 1950s and 1960s, and we have achieved a 90%+ rate of immunization among school-children.<sup>2</sup>It is not a perfect vaccine; some persons are only partially protected and some not at all. Furthermore, it has a high frequency of transient, nondamaging side effects, a lesser frequency of potentially serious adverse effects, and a remote risk of permanent neurological sequelae or death.<sup>3</sup> Given this brief summary, one might expect cautious rejoicing. We can rejoice in that, once again, preventive measures seem to have triumphed in diminishing disease; indeed, the reduction in pertussis is striking and impressive. We are
Heparin Treatment of Bleeding
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Aerospace Medicine, St. Paul
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health Effects of Asbestos and Nonasbestos Fibers
Authors: Omowunmi Y. O. Osinubi, Michael Gochfeld, Howard M. Kipen
Journal: Environmental Health Perspectives (2000)

Exposures to asbestos and synthetic fibers remain areas of great concern in the field of occupational lung disease.Despite extensive study, the health effects associated with fibers remains an area of substantial controversy.In particular, effects of fibers at relatively low doses, particularly for mesothelioma, remain a matter of evolving opinion, especially when integrated with the divergence of opinion on relative pathogenicity of different fiber types.Mechanistic studies continue to provide a window into pathogenesis and some hope for understanding dose-response relationships at the lower levels seen in contemporary Western workplaces and the general environment.Changes in clinical assessment based on use of new chest imaging techniques beyond the traditional plain film are also an area of evolution and begin to challenge B-reading as the definitive tool for noninvasive assessment of disease.Public health concerns have to a great extent been transported to the developing world where there is a strong trend toward increased use of asbestos, although it has been virtually eliminated from commerce in most developed countries.For nonasbestos fibers, the major unsettled issues are their relative potencies as carcinogens for the human lung and mesothelium and the need to sort out the relation between physical and chemical properties of these fibers and their pathogenicity.The recent discovery of "flock worker's lung" due to synthetic fibers once again alerts us to emerging diseases associated with new technologies.
Oral Poliomyelitis Vaccines
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Current Therapeutic Research, New York
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P027: Type 2 Diabetes Status Does nNt Impact Perceived Barriers to Healthy Eating Among Overweight/Obese Hispanic Women
Authors: Sonia Vega-López, Nangel M Lindberg, Michael C Leo, Milena Petrovic, Mayra Arias-Gastélum, Elizabeth Shuster, Erin S LeBlanc, Victor J Stevens, Tanya J Kapka, Richard T Meenan
Journal: Circulation (2017)

Background: Hispanic women are disproportionately affected by cardiometabolic disease risk factors including increased adiposity. Addressing barriers to dietary change is an important strategy for ensuring success of behavioral weight loss interventions. However, perceived barriers to healthy eating among Hispanic women have not been thoroughly studied, and how a type 2 diabetes (T2D) or prediabetes (preD) diagnosis and HbA1c levels are related to those perceptions are unknown. Objective: To examine the association of perceived barriers to healthy eating for weight loss with HbA1c and T2D status among Hispanic women. Methods: Participants (n=197; 86.9±16.6 kg; 36.6±6.5 kg/m 2 ) of De Por Vida , a culturally-tailored weight loss intervention for adult Hispanic women with or at risk for T2D, completed the Barriers to Healthy Eating (BHE) scale at baseline. The BHE scale was translated into Spanish and slightly modified for use with low-literacy participants. Possible BHE scores range from 22 to 110 for the overall scale, from 11 to 55 for the emotions subscale, from 8 to 40 for the daily mechanics subscale, and from 3 to 15 for the social support subscale, with higher scores indicating greater perceived barriers. Participants were categorized based on their baseline HbA1c concentration as follows: at risk for T2D (n=54; HbA1c &lt;5.7% but history of gestational diabetes, hyperlipidemia or hypertension), preD (n=86; HbA1c ≥5.7% but &lt;6.5%) or T2D (n=57; HbA1c ≥6.5%), regardless of diagnosis in the medical record. Results: Among all participants, total BHE score was 65.3±20.7, and scores for the emotions, daily mechanics, and social support subscales were 33.3±11.7, 24.8±8.3, and 7.4±3.2, respectively. HbA1c concentrations were negatively correlated with BHE total (r=-.13; p=.06), emotional (r=-.14; p=.06), and social support scores (r=-.17; p=0.02). When HbA1c was examined as a categorical variable (i.e., T2D status) there were no significant associations with any BHE scale score. Conclusions: In general, participants’ rated their perceived barriers to healthy eating as relatively important problems to their ability to lose weight. There was no evidence that having a preD or T2D diagnosis was associated with their perception of barriers. Given the significant health and economic consequence of a T2D diagnosis, interventions should better address perceived barriers to healthy eating in the preD and T2D population. Funding source: NIH/NIDDK – 1R01DK099277.
Correction:<i>HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma</i>
Authors: Jared E Lopes, Heather L Flick, Chunhua Wang, Juan C Alvarez, Heather C Losey
Journal: Journal for ImmunoTherapy of Cancer (2020)

In this article, the last panels in figure 3C and 3D incorrectly show the same image.The corrected figure 3 is shown below Figure 3. Representative micrographs of CD8 (A) and CD4 (B) expression and the corresponding negative controls within the tumor.Scatter plot depicted the correlation between HHLA2 and PD-L1 expression and classic subsets of T cells.(C) The correlation of HHLA2 expression and CD8+ T cells and CD4+ T cells in the training cohort and validation cohort.(D) The correlation of PD-L1 expression and CD8+ T cells and CD4+ T cells in the training cohort and validation cohort.(E) The correlation of the HHLA2/PD-L1 co-expression and CD8+ T cells and CD4+ T cells in the training cohort and validation cohort.Group I: HHLA2 (-)/PD-L1 (-); group II: HHLA2 (+)/PD-L1 (-) or HHLA2 (-)/PD-L1 (+); group III: HHLA2 (+)/PD-L1 (+).HHLA2, human endogenous retrovirus-H long terminal repeat-associating protein 2; PD-L1, programmed death 1 ligand 1.Additionally, in the Results section titled 'Immune classification for ccRCC' the sentence "1.9% (4/206) and 2.5% (5/197) belong to type AIII, defined as negative Correction on September 1,